A revolutionary, needle-free technology that has been designed to deliver retina therapies non-invasively, to the back of the eye, has been launched.
Retina recap: EMA and US FDA approvals, March 2025
Regulatory agencies issued approvals for new treatments and expanded uses of existing therapies in the retina space
PHOTON Results and Their Relation to DME Patients in Your Practice
John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.
Opthea discontinues COAST and ShORe sozinibercept combination therapy trials
Both trials failed to meet their primary endpoints for treatment of age-related macular degeneration
PULSAR Results and Their Relation to nAMD Patients in Your Practice
John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.
EMA grants positive CHMP opinion for low-dose atropine SYD-101 (Ryjunea, Sydnexis)
A pivotal phase 3 clinical trial found that SYD-101 met its 3-year primary endpoint for slowing paediatric myopia progression
New study investigates ocular involvement in multiple myeloma
Hematologists and ophthalmologists could work together for earlier diagnoses, research findings indicate